Pular para o conteúdo
Merck
Todas as fotos(1)

Key Documents

View All Documentation

P2116

Sigma-Aldrich

Pirfenidone

≥97% (HPLC), powder, antifibrotic agent

Sinônimo(s):

5-Methyl-1-phenyl-2-(1H)-pyridone

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C12H11NO
Número CAS:
53179-13-8
Peso molecular:
185.22
Número MDL:
MFCD00866047
Código UNSPSC:
12352200
ID de substância PubChem:
24278625
NACRES:
NA.77

product name

Pirfenidone, ≥97% (HPLC)

Ensaio

≥97% (HPLC)

forma

powder

solubilidade

H2O: >10 mg/mL at 60 °C (warming for 30 minutes)
DMSO: >20 mg/mL

originador

Shionogi

cadeia de caracteres SMILES

O=C(C=CC(C)=C1)N1C2=CC=CC=C2

InChI

1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3

chave InChI

ISWRGOKTTBVCFA-UHFFFAOYSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

Pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone) is a synthetic derivative of pyridine.

Aplicação

Pirfenidone has been used:
  • as a post-operative eye drop in rabbits to analyse its antifibrotic effect to improve glaucoma filtration surgery
  • as an anti-scarring agent to examine whether it affects the foreign body reaction after glaucoma drainage device (GDD) implantation in a rabbit
  • to test its antifibrotic potential in primary cultures of human orbital fibroblasts (hOFs)
  • as tumor necrosis factor (TNFα) inhibitor to study its effect in hypoxia

Ações bioquímicas/fisiológicas

Pirfenidone inhibits collagen production and fibroblast proliferation. It has shown antifibrotic and anti-inflammatory properties in variety of animal models of pulmonary fibrosis, and in clinical trials.
Pirfenidone is used to treat idiopathic pulmonary fibrosis (IPF). It helps to decrease the weakening of lung function decline and ameliorate progression-free survival. Pirfenidone can repress the multiplication and contraction of collagen of human tenon′s fibroblasts.

Características e benefícios

This compound was developed by Shionogi. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogramas

Exclamation mark
GHS07

Palavra indicadora

Warning

Frases de perigo

H302

Declarações de precaução

P264 - P270 - P301 + P312 - P501

Classificações de perigo

Acute Tox. 4 Oral

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Equipamento de proteção individual

dust mask type N95 (US), Eyeshields, Gloves

Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 9

1 of 9

PF-3644022 hydrate ≥98% (HPLC)

Sigma-Aldrich

PZ0188

PF-3644022 hydrate

3-Hydroxy-2-methylpyridine 99%

Sigma-Aldrich

268534

3-Hydroxy-2-methylpyridine

Toremifene citrate salt ≥98% (HPLC)

Sigma-Aldrich

T7204

Toremifene citrate salt

5-Hydroxy-2-methylpyridine 99%

Sigma-Aldrich

107263

5-Hydroxy-2-methylpyridine

2-Amino-5-methylpyridine 99%

Sigma-Aldrich

A75684

2-Amino-5-methylpyridine

Relaxin-2 human recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture

Sigma-Aldrich

SRP3147

Relaxin-2 human

X-34 ≥90% (HPLC)

Sigma-Aldrich

SML1954

X-34

Axitinib ≥98% (HPLC)

Sigma-Aldrich

PZ0193

Axitinib

SIS3 ≥98% (HPLC), powder

Sigma-Aldrich

S0447

SIS3

Natalie J Carter
Drugs, 71(13), 1721-1732 (2011-09-10)
Pirfenidone is an orally administered pyridine that has orphan designation for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) in the EU. Pirfenidone 2403 mg/day for 72 weeks administered to patients with IPF was associated with a significantly lower
Pathobiology of Novel Approaches to Treatment
AIDS Patient Care and STDs, 26(146), 170057-170057 (2018)
Ole Hilberg et al.
The clinical respiratory journal, 6(3), 131-143 (2012-06-16)
Pirfenidone has been shown in three recently published trials to slow down the progression of the devastating interstitial lung disease, idiopathic pulmonary fibrosis (IPF). The precise mechanisms that initiate and perpetuate the histopathological process leading to lung fibrosis in IPF
Hua Zhong et al.
Investigative ophthalmology & visual science, 52(6), 3136-3142 (2011-02-19)
To investigate whether topical administration of pirfenidone eye drops could be used to prevent postoperative scarring in a rabbit model of experimental glaucoma filtration surgery. In a randomized, controlled, masked-observer study, 40 rabbits underwent trabeculectomy in the right eyes and
Peyman Bizargity et al.
Transplantation, 94(2), 114-122 (2012-06-30)
Pirfenidone (PFD) is an antifibrotic agent with beneficial effects on proinflammatory disorders. In this study, we further investigated PFD and long-acting form, "deuterated PFD," immune-modulating properties by evaluating their effects on mouse dendritic cells (DCs). The effects of PFD on
Exibir todos os documentos relacionados

Conteúdo relacionado

Discover Bioactive Small Molecules for Immunology Research

We offer agonists, antagonists, modulators and other bioactive small molecules for immune system signaling target identification and validation, as well as a variety of antibiotics, antivirals, and antifungals.

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica